# XRAY earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/XRAY) · [Earnings tab](https://www.lopjlb.com/stock/XRAY?tab=earnings) Updated: 2026-08-06T07:02:42 Quarters analyzed: 8 ## Cross-quarter narrative Across the series of earnings calls, Dentsply Sirona moved from a period of declining revenue and vague guidance in 2024 toward a more structured turnaround anchored by the Return‑to‑Growth plan introduced in late 2025. Early calls highlighted Byte regulatory suspension, large goodwill impairments and a shrinking implant share, prompting lowered FY outlooks. By Q2 2025 the new CEO emphasized stability and margin expansion despite a 7 % sales dip, while the company continued to absorb impairments and tariff headwinds. The Q3 2025 call detailed the four‑pillar Return‑to‑Growth framework, modest margin improvement, dividend reductions and a series of on‑track restructuring actions. In Q1 2026 revenue flattened, margin pressure persisted but was expected to recover, and the firm reaffirmed its outlook while eliminating the dividend to free cash for debt reduction and R&D. Throughout, tariff‑related cost pressure, U.S. commercial challenges, and a slowing Chinese VBP phase 2 have been recurring concerns, with newer macro‑geopolitical and European destocking risks emerging in 2026. ## Latest CallCard · Q1 Dentsply Sirona Q1 2026 showed flat revenue, margin pressure from tariffs and mix, early cost cuts and AI rollout, and reaffirmed its 2026 outlook while noting benefits from the Return‑to‑Growth plan will materialize later in the year and into 2027‑28. **Guidance:** maintained — Management reaffirmed 2026 net sales of $3.5‑$3.6 bn and adjusted EPS of $1.40‑$1.50. **Tone:** mgmt 0.3 · Q&A pressure 0.6 · divergence 0.4 Management expressed confidence in the Return‑to‑Growth plan, highlighted early progress and maintained the full‑year outlook. ### Demand visibility Visibility improving, especially in the second half of the year. Management cited early traction with new U.S. distributors (Atlanta Dental Supply, Benco), ongoing DSO conversations and a stronger outlook for APAC and EMEA as the year progresses. ### Margins / costs Margins pressured by tariffs, mix and inventory, but expected to recover. Tariff impacts and a negative sales mix drove a 430‑bp EBITDA margin decline; management expects at least a 300‑bp gross‑margin recovery in Q2‑Q3 as tariffs ease and inventory effects normalize. ### Capital allocation Prioritizing debt reduction, R&D and commercial growth; dividend eliminated for flexibility. $80 M of debt retired in Q1, $20 M OpEx savings reinvested into R&D, clinical education and commercial capabilities, with share‑repurchase timing to be evaluated later in the year. ### Milestones - **Return‑to‑Growth action plan** [on_track]: 24‑month plan launched in Q1; cost‑benefit timing expected in Q4 with larger impact in 2027‑28. - **U.S. commercial restructuring** [on_track]: New leadership hires and expanded sales‑force training underway. - **Atlanta Dental Supply distribution agreement** [delivered]: Effective Aug 1, adds fourth new distributor in 2024. - **Benco CEREC system installation** [delivered]: First system installed ahead of schedule. - **Smart View‑Detect launch** [new]: AI‑enabled diagnostic aid cleared FDA and CE, improves detection sensitivity by ~46%. - **Reciproc Minima & X‑Smart Go launch** [new]: New endodontic files and cordless motor introduced to simplify workflows. - **Dental MRI FDA clearance** [new]: First dental‑dedicated MRI cleared, expanding soft‑tissue imaging portfolio. - **AI‑enabled productivity tools rollout** [on_track]: Initial deployment in Q1 with broader rollout planned for the year. ### Fears / risks - **Macro/geopolitical**: Ongoing geopolitical tensions and macro uncertainty could affect demand across regions. - **Tariff headwinds**: Higher tariffs on imported components reduced gross margin and sales mix. - **European destocking**: Unexpected destocking in Europe contributed to a 7% decline in EDS sales. - **Input‑cost inflation**: Higher oil and freight costs are being monitored for potential impact on pricing and margins. - **Private‑label competition**: Shift toward private‑label consumables could erode market share if not countered. - **Implant volume weakness**: Implant segment underperformed, requiring stronger education and execution. - **Drop‑ship inventory build‑out**: Inventory buildup under new capital model expected to affect margins from Q2 onward. - **Execution risk of Return‑to‑Growth**: Successful delivery of cost savings and growth initiatives remains uncertain. ### Key quotes > “Q1 marked the start of executing the DENTSPLY SIRONA Return-to-Growth action plan.” — Daniel Scavilla > “Adjusted EBITDA margins declined 430 basis points, resulting from a 560 basis points decline in gross profit, driven by lower volumes, sales mix and tariff impacts.” > “In Q1, we began deploying AI-enabled tools and select workflows to improve productivity with broader rollout plan throughout the year.” ## Quarter one-liners - **2026 Q1:** Dentsply Sirona Q1 2026 showed flat revenue, margin pressure from tariffs and mix, early cost cuts and AI rollout, and reaffirmed its 2026 outlook while noting benefits from the Return‑to‑Growth plan will materialize later in the year and into 2027‑28. - **2025 Q4:** — - **2025 Q3:** New CEO Dan Scavilla unveils Return-to-Growth plan with 4 pillars after 90 days; Q3 sales down 5% reported (-8% cc), guidance lowered to $3.6-3.7B sales, -5% to -4% cc, EPS ~$1.60; CFO departed, $263M impairments, investing in R&D, commercial, supply chain. U.S. down 22% (-9.7% ex items), Europe +2. - **2025 Q2:** New CEO Scavilla emphasizes stability, customer focus, and acceleration; Q2 sales down 7% cc but margins expand 360bps; guidance maintained despite $80M annualized tariff headwind. Impairments of $214M taken on OIS/CTS goodwill. Implant transition and Byte wind-down weigh on top line. DS Core at 50k - **2025 Q1:** Dentsply Sirona Q1 organic sales -4.4% (incl. -4% Byte), EBITDA margin +220bps, EPS +3.7%; maintains 2025 outlook amid tariff headwinds, DS Core traction (50k devices), supply chain optimization, CFO search ongoing.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Prepared remarks express confidence in Q1 - **2024 Q4:** Dentsply Sirona Q4 2024: organic sales -10.7% YoY, 2025 guide -2% to -4% organic; Byte charges $62M, $370M impairments; SureSmile & imaging bright spots; Wellspect strategic review; Phase II transformation on track. Adjusted EPS $0.26 vs $0.44 prior year. Free cash flow ~$300M guided for 2025. Phase - **2024 Q3:** DENTSPLY SIRONA Q3 revenue $951M (+1.3% organic), but lowered 2024 outlook due to Byte regulatory suspension and equipment weakness; $500M goodwill impairment; implants share loss prompts commercial reset.','tone': {'mgmt': -0.2, 'mgmt_rationale': 'Management acknowledges Byte suspension, implant sh - **2024 Q2:** Q2 revenue $984M (-4.2% YoY), CTS weak but other segments grow; FY guidance lowered to $3.86-3.90B sales, organic -1% to flat, EPS $1.96-2.02; Phase 2 restructuring targets $80-100M synergies, inside sales build, Patterson equipment non-renewal. Strong cash flow enables $380M shareholder returns. Ma ## Theme arcs - **Revenue trend** (deteriorating): Revenue fell YoY from 2024 Q2 through 2025 Q3, flattening in 2026 Q1 - **Margin trend** (improving): Margins expanded in Q2 2025 and Q3 2025 despite sales decline - **Guidance outlook** (deteriorating): Guidance lowered multiple times from 2024 through Q3 2025 - **Transformation initiatives** (new): Return‑to‑Growth plan launched Q3 2025 - **Dividend policy** (deteriorating): Shift from $32M dividend in Q3 2025 to elimination in Q1 2026 - **Tariff impact** (deteriorating): Tariff headwinds cited repeatedly as margin and volume pressure - **China VBP phase 2** (deteriorating): Slowdown in implant volumes noted Q3 2025 and persists - **U.S. commercial restructuring** (improving): Restructuring on track per Q3 2025 and Q1 2026 calls - **AI/automation rollout** (new): Early AI rollout mentioned Q1 2026 - **Capital allocation (deleveraging)** (improving): Debt reduction prioritized and dividend cut in Q1 2026 ## Guidance path 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:lowered → 2025 Q4:vague → 2026 Q1:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/XRAY`